Mitoxantrone treatment of multiple sclerosis: safety considerations.
Pratt
Robert G
RG
Boehm
Gerard A
GA
Kortepeter
Cindy M
CM
Racoosin
Judith A
JA
D000700:Analgesics / Q000008:administration & dosage / Q000009:adverse effects; D009202:Cardiomyopathies / Q000139:chemically induced* / Q000000981:diagnostic imaging; D004305:Dose-Response Relationship, Drug; D064420:Drug-Related Side Effects and Adverse Reactions; D042241:Early Diagnosis; D004452:Echocardiography / Q000592:standards; D015637:Gated Blood-Pool Imaging / Q000592:standards; D006321:Heart / Q000187:drug effects* / Q000503:physiopathology; D006333:Heart Failure / Q000139:chemically induced / Q000000981:diagnostic imaging; D006801:Humans; D008942:Mitoxantrone / Q000008:administration & dosage / Q000009:adverse effects*; D008991:Monitoring, Physiologic / Q000592:standards; D009103:Multiple Sclerosis / Q000188:drug therapy*; D028761:Withholding Treatment / Q000592:standards
D000700:Analgesics; D008942:Mitoxantrone